• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Erratum: Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial.

出版信息

J Clin Oncol. 2023 Jul 20;41(21):3767. doi: 10.1200/JCO.23.00901. Epub 2023 May 9.

DOI:10.1200/JCO.23.00901
PMID:37159880
Abstract
摘要

相似文献

1
Erratum: Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial.勘误：纳武利尤单抗联合卡博替尼与舒尼替尼用于晚期肾细胞癌（aRCC）一线治疗的3年随访：3期CheckMate 9 ER试验结果
J Clin Oncol. 2023 Jul 20;41(21):3767. doi: 10.1200/JCO.23.00901. Epub 2023 May 9.
2
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.纳武利尤单抗联合卡博替尼与舒尼替尼用于晚期肾细胞癌一线治疗（CheckMate 9ER）：一项开放标签、随机、III 期临床试验的长期随访结果。
Lancet Oncol. 2022 Jul;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Epub 2022 Jun 7.
3
Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States.纳武单抗联合卡博替尼对比舒尼替尼作为美国晚期肾细胞癌一线治疗的成本效益
Front Pharmacol. 2021 Dec 13;12:736860. doi: 10.3389/fphar.2021.736860. eCollection 2021.
4
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.一线纳武利尤单抗联合卡博替尼与舒尼替尼治疗晚期肾细胞癌患者的患者报告结局：CheckMate 9ER 开放标签、随机、III 期试验。
Lancet Oncol. 2022 Feb;23(2):292-303. doi: 10.1016/S1470-2045(21)00693-8. Epub 2022 Jan 12.
5
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial.CheckMate 214 试验中未经肾切除术且可评估主要肾脏肿瘤患者的一线纳武利尤单抗联合伊匹木单抗与舒尼替尼比较。
Eur Urol. 2022 Mar;81(3):266-271. doi: 10.1016/j.eururo.2021.10.001. Epub 2021 Nov 5.
6
Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma.卡博替尼联合纳武利尤单抗治疗晚期肾细胞癌的研究进展。
Target Oncol. 2022 Mar;17(2):193-201. doi: 10.1007/s11523-022-00866-1. Epub 2022 Feb 17.
7
Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.纳武利尤单抗联合卡博替尼与舒尼替尼作为晚期肾细胞癌一线治疗的成本效益分析。
Immunotherapy. 2022 Aug;14(11):859-869. doi: 10.2217/imt-2021-0156. Epub 2022 Jun 27.
8
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.纳武利尤单抗联合伊匹木单抗与舒尼替尼一线治疗晚期肾细胞癌：III期CheckMate 214试验的4年延长随访
ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079.
9
Cabozantinib exposure-response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma.卡博替尼暴露反应分析：CheckMate 9ER 试验nivolumab 联合卡博替尼对比舒尼替尼作为一线晚期肾细胞癌的治疗。
Cancer Chemother Pharmacol. 2023 Feb;91(2):179-189. doi: 10.1007/s00280-022-04500-9. Epub 2023 Jan 10.
10
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.纳武利尤单抗联合伊匹单抗对比舒尼替尼用于晚期肾细胞癌的一线治疗：来自一项随机、对照、III 期临床试验的疗效和安全性结果的扩展随访。
Lancet Oncol. 2019 Oct;20(10):1370-1385. doi: 10.1016/S1470-2045(19)30413-9. Epub 2019 Aug 16.

引用本文的文献

1
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1).帕博利珠单抗联合阿昔替尼与纳武利尤单抗联合卡博替尼作为转移性肾细胞癌患者一线治疗的回顾性真实世界比较（ARON-1）
Cancer Immunol Immunother. 2025 May 27;74(7):225. doi: 10.1007/s00262-025-04043-x.
2
Comparison of machine learning methods for Predicting 3-Year survival in elderly esophageal squamous cancer patients based on oxidative stress.基于氧化应激的老年食管鳞癌患者 3 年生存预测的机器学习方法比较。
BMC Cancer. 2024 Nov 21;24(1):1432. doi: 10.1186/s12885-024-13115-7.
3
Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data.
基于长期随访数据结果的晚期肾细胞癌一线治疗的最佳选择
Transl Androl Urol. 2024 Aug 31;13(8):1336-1340. doi: 10.21037/tau-24-172. Epub 2024 Aug 12.
4
Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma.转移性肾细胞癌的现代一线治疗的医疗资源利用。
JAMA Netw Open. 2024 Jul 1;7(7):e2422674. doi: 10.1001/jamanetworkopen.2024.22674.
5
2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium Meeting highlights.2024年美国临床肿瘤学会泌尿生殖系统（ASCO-GU）癌症研讨会会议亮点。
Can Urol Assoc J. 2024 May;18(5):E179-E186. doi: 10.5489/cuaj.8797.
6
Banana-shaped survival curves of metastatic renal cell carcinoma treated with first-line immune-combinations, not just a matter of "palateau".一线免疫联合治疗转移性肾细胞癌的香蕉形生存曲线，不只是“高原”那么简单。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2351669. doi: 10.1080/21645515.2024.2351669. Epub 2024 May 17.
7
Tumor microenvironment and clinical efficacy of first line immunotherapy-based combinations in metastatic renal cell carcinoma.肿瘤微环境与转移性肾细胞癌一线免疫治疗联合方案的临床疗效。
Med Oncol. 2024 May 13;41(6):150. doi: 10.1007/s12032-024-02370-0.
8
[Not Available].[无可用内容]
CMAJ. 2024 May 5;196(17):E601-E607. doi: 10.1503/cmaj.230356-f.
9
Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.晚期肾细胞癌的治疗管理：拉丁美洲肿瘤协作组（LACOG）和拉丁美洲肾癌协作组（LARCG）的共识更新。
J Cancer Res Clin Oncol. 2024 Apr 9;150(4):183. doi: 10.1007/s00432-024-05663-z.
10
Advances in the management of renal cell carcinoma.肾细胞癌管理方面的进展
CMAJ. 2024 Feb 25;196(7):E235-E240. doi: 10.1503/cmaj.230356.